ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib mesylate (IM; Glivec), formerly STI57 (1), was the first available BCR/ABL-targeted therapy and produced complete cytogenetic responses in 70–85% of patients with CML in the early chronic phase (CP) (2).